"Placebo controlled" simply means an inert substitute to the treatment under test will be administered to randomly selected patients instead of the active treatment in order to maintain double blinding and avoid bias. The rest of the standard of care will be the same for all of the trial participants. Your lack of knowledge of clinical trials means your posts here probably cause a lot of confusion.
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-223
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.050B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32370 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 60258 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |